Pair page — what's published on the two together
GHRP-2 with GHRP-6
Studied together only as part of a three-peptide regimen (GHRP-2, GHRP-6 and sermorelin) in 14 men on testosterone, in 2017.
The receipt
1 study gave them to people together
Human pilots · 1 record review, 14 men (2017)
- Evidence on the combination
- Human pilots
What each does alone
- Muscle & strength · Daily shotGHRP-2GH secretagogueClinic users inject it 2–3 times a day. Its only approval: a one-shot growth-hormone test in Japan, 2004.Controlled trialsGray marketChecked Oct 18
- Muscle & strength · Daily shotGHRP-6GH secretagogueThe 1984 original, now taken mostly for its hunger kick. Its GH data in people: short tests, 1 record review.Human pilotsGray marketChecked Oct 13
Mechanism overlap · reasoning, not evidence
- GHRP-2
- Peptide — Growth Hormone Secretagogue (Ghrelin Receptor Agonist)
- GHRP-6
- Peptide — Growth Hormone Secretagogue (Ghrelin Receptor Agonist)
- Shared mechanism tag
- ghrelin receptor agonist
- Shared mechanism tag
- growth hormone secretagogue
Reasoning, not evidence: what each is described to do says nothing about what they do together.
What the studies found
Men on testosterone therapy (Sigalos et al., 2017)
- What was given — A retrospective review of 105 hypogonadal men on testosterone therapy who were prescribed GHRP-6, GHRP-2 and sermorelin together, 100 mcg of each injected under the skin three times a day (started 2012–2015). 14 men met the strict compliance criteria and were analysed.
- What it found — IGF-1 rose from 159.5 to 239.0 ng/mL (p < .0001) over a mean 134 days of treatment. Men also taking an aromatase inhibitor or tamoxifen had smaller rises. In the full text, testosterone and free testosterone rose significantly from 90 days on; LH, FSH and estradiol did not change.
- Limits — No control group, and the three peptides were always given together, so no single peptide's effect can be separated. Anthropometric data were missing for most men.
No study has given GHRP-2 and GHRP-6 together without sermorelin.
Legal Status
GHRP-2: Gray market. FDA said no to injectable and nasal forms — on the do-not-compound list.
GHRP-6: Gray market. FDA said no — on the do-not-compound list.
References
- Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017;11(6):1752-1757. PMID: 28830317.
Checked 14 Oct 2026 | A literature lookup, not a recommendation to combine anything.